Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma

Cisplatin is a first-line chemotherapy drug for lung adenocarcinoma (LUAD). However, its therapeutic efficacy is limited because of serious side effects and acquired drug resistance. Targeting HER2 has been proven to be a viable therapeutic strategy against LUAD. Moreover, inetetamab, an innovative...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jinfang, He, Yuchao, Zhu, Fuyi, Gong, Wenchen, Zuo, Ran, Wang, Yu, Luo, Yi, Chen, Liwei, Wang, Chengmeng, Huo, Gengwei, Lu, Hailing, Liu, Zhiyong, Chen, Peng, Guo, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496496/
https://www.ncbi.nlm.nih.gov/pubmed/37705753
http://dx.doi.org/10.7150/ijbs.82980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496496/
https://www.ncbi.nlm.nih.gov/pubmed/37705753
http://dx.doi.org/10.7150/ijbs.82980

Ejemplares similares